Workflow
龙津药业(002750) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue decreased by 32.09% to CNY 57,101,990.19 for the current period, and decreased by 25.22% to CNY 188,252,316.89 year-to-date[7] - Net profit attributable to shareholders decreased by 94.19% to CNY 209,066.80 for the current period, and decreased by 89.33% to CNY 1,549,207.01 year-to-date[7] - Basic earnings per share dropped by 94.44% to CNY 0.0005 for the current period, and decreased by 89.26% to CNY 0.0039 year-to-date[7] - Total operating revenue for Q3 2019 was CNY 57,101,990.19, a decrease of 32.0% compared to CNY 84,080,613.79 in the same period last year[35] - Net profit for Q3 2019 was CNY -597,735.04, compared to a net profit of CNY 3,601,262.57 in Q3 2018, indicating a significant decline[37] - The company reported a total comprehensive income of ¥729,145.60, significantly lower than ¥14,523,775.71 in the previous period[45] Assets and Liabilities - Total assets increased by 4.58% to CNY 823,588,973.70 compared to the end of the previous year[7] - The total liabilities increased to CNY 137,640,065.73 from CNY 131,616,795.52, marking a rise of about 4.06%[29] - The company's total non-current assets reached CNY 342,193,829.77, up from CNY 314,980,193.45, indicating an increase of about 8.63% year-over-year[27] - Total current assets amounted to CNY 472,569,549.40, with cash and cash equivalents at CNY 384,283,633.27[60] - The total liabilities decreased to CNY 103,312,609.31 from CNY 131,504,054.02, reflecting a reduction of 21.4%[34] - Total liabilities reached CNY 131,504,054.02, with non-current liabilities at CNY 32,181,842.92[67] Cash Flow - Net cash flow from operating activities increased by 202.12% to CNY 13,358,466.06 for the current period[7] - Cash inflow from operating activities was CNY 237,487,982.25, down from CNY 306,319,007.08 in the previous period, representing a decrease of approximately 22.4%[51] - Cash outflow for investment activities totaled CNY 73,145,043.47, significantly lower than CNY 1,011,690,434.20 in the previous period[53] - Cash inflow from financing activities was CNY 19,250,900.00, while cash outflow was CNY 12,015,000.00, resulting in a net cash flow of CNY 7,235,900.00[53] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,670[9] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 42.38% of the shares, totaling 169,724,647 shares[9] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[11] Research and Development - The company reported a 148.04% increase in development expenditures to ¥11,789,673.91, driven by increased R&D investments in generic drugs and re-evaluation of already listed products[14] - Research and development expenses for Q3 2019 were CNY 3,995,816.06, down 57.2% from CNY 9,336,728.52 in the same quarter last year[35] - Research and development expenses were ¥13,993,041.17, a decrease of 38.5% from ¥22,687,720.43 in the previous period[42] Inventory and Receivables - Accounts receivable decreased by 30.31% to ¥25,904,415.87 from ¥37,172,011.23, attributed to successful collection efforts during the period[14] - Inventory increased by 46.80% to ¥39,906,415.07 due to the acquisition of the aforementioned companies[14] - The company reported a rise in other receivables to CNY 19,498,870.45 from CNY 2,921,427.39, an increase of about 570.0%[26] Acquisitions and Investments - The company completed the acquisition of Nanjiang Longjin Biotechnology Co., Ltd. and Nanjiang Longjin Agricultural Technology Co., Ltd., resulting in a 60.40% increase in intangible assets to ¥42,138,570.22[14] - The company’s goodwill increased to ¥6,999,586.78 due to the acquisitions, marking a 100% increase[14] Financial Ratios - The company’s total liabilities to equity ratio stands at approximately 0.20, indicating a conservative leverage position[62]